Company intelligence / Profile preview

Labomed

Athens/Koropi, Attika, Greece6sense.com ↗

Ownership: Private
Development stage: Commercial

Overview

Laboserve/Labomed specializes in the development and manufacturing of generic and added-value medicines in oral liquid forms. Their portfolio includes commercialized products for CNS disorders, pain management, respiratory conditions, and urological indications. The company holds EU-GMP certification and focuses on both European and US markets. No clinical trial results are published as they focus on generics/hybrids rather than novel therapeutics.

Therapeutic areas: PulmonologyPsychiatryNeurology
Modalities: Small moleculeOral liquid formulationsGeneric drugsHybrid drugs
Industry: Biotech

Drug pipeline

5 assets

carbocisteine

Commercial

Indications: Respiratory tract infections

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Labomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Labomed.

Explore the full profile